Paragonix Technologies clinical trials
Paragonix Technologies is the lead sponsor of 3 current clinical trials in our USA, UK, Spain, Austria and Belgium registers. None of its ClinicalTrials.gov trials is recruiting at the moment. All registered phases are Observational. The most-studied condition is Heart Diseases.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by Paragonix Technologies
3 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
NCT04930289 · Interstitial Lung Disease, COPD, Cystic Fibrosis
|
Observational | By invitation | 2021-10 | USA, Belgium |
|
Global Utilization And Registry Database for Improved heArt preservatioN
NCT04141605 · Heart Diseases, Heart Failure, Heart Defects, Congenital
|
Observational | By invitation | 2020-02 | UK, USA, Spain, Austria |
|
Global Utilization And Registry Database for Improved preservAtion of doNor Livers
NCT05082077 · Liver Diseases, Liver Dysfunction, Liver Transplant Disorder
|
Observational | By invitation | 2022-03 | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Conditions in Paragonix Technologies trials
11 conditionsBy trial register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 0 |
| Clinical trials in UK | 1 | 0 |
| Clinical trials in Spain | 1 | 0 |
| Clinical trials in Austria | 1 | 0 |
| Clinical trials in Belgium | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Other sponsors in Heart Diseases
| Sponsor | Trials |
|---|---|
| Weill Medical College of Cornell University | 2 |
| Kiniksa Pharmaceuticals International | 1 |
| Teleflex | 1 |
| CMC Ambroise Paré | 1 |
| Groupe Hospitalier Pitie-Salpetriere | 1 |
| Jung-min Ahn | 1 |
Sponsors with the most current trials registered for this condition.
Questions about Paragonix Technologies trials
How many clinical trials does Paragonix Technologies sponsor?
Paragonix Technologies is the lead sponsor of 3 current trials on ClinicalTrials.gov in our USA, UK, Spain, Austria and Belgium registers, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Paragonix Technologies trials recruiting?
Not at the moment. None of its 3 ClinicalTrials.gov trials is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.